Share Icon Health Study Area: Cardiovascular Disease Chevron Icon Health Study Area: Genitourinary For Patients Health Study Area: Lung Cancer Page Icon Phone Icon For Caregivers Health Study Area: AutoImmune Disease Health Study Area: Melanoma Location Icon Print YouTube Icon For Parents Health Study Area: Lung Cancer Print Created with Sketch. Help Icon Green Check Icon Search Icon Instagram Created with sketchtool. Direction Arrow Icon Error Icon For Parents Health Study Area: Blood Cancer Help Icon Health Study Area: NASH Gender Both Bookmark Icon Health Study Area: Melanoma Created with Sketch. Glossary Print Health Study Area: Blood Cancer Health Study Area: Genitourinary Health Study Area: Gastrointestinal Cancer Mobile Menu Icon Created with Sketch. Health Study Area: Cardiovascular Disease Health Study Area: Women's Cancer Communities Map Icon Created with Sketch. For Caregivers Health Study Area: Fibrosis Health Study Area: AutoImmune Disease FAQs Health Study Area: Head and Neck Cancer Created with Sketch. For Clinicians Chevron Right Icon Gender Female Health Study Area: Breast Cancer Direction Arrow Icon Gender Both Right Arrow Icon LinkedIn Icon Green Check Icon Gender Male Health Study Area: Fibrosis For Patients Twitter Icon Email Icon Facebook Icon Health Study Area: Gastrointestinal Cancer Health Study Area: Head and Neck Cancer For Clinicians External Link Icon
Szukaj Study Connect
  • NCT03989414

Recruiting

A Study to Determine the Recommended Dose and Regimen and Evaluate the Safety and Preliminary Efficacy of CC-92480 in Combination With Standard Treatments in Subjects With Relapsed or Refractory Multiple Myeloma (RRMM) and Newly Diagnosed Multiple Myeloma (NDMM) - CC-92480-MM-002

Zaktualizowano: 8 styczeń, 2024   |   ClinicalTrials.gov

Celgene jest spółką zależną w całości należącą do Bristol-Myers Squibb 

Wydruk podsumowania

BIERZESZ POD UWAGĘ TO BADANIE?
Wydrukuj tę stronę i przewodnik po badaniu, aby pomóc sobie w rozmowie z lekarzem.
Skorzystaj z Przewodnika po badaniu, aby dowiedzieć się o procesie badań klinicznych. Zapoznaj się z kluczowymi czynnikami, które należy wziąć pod uwagę przed podjęciem decyzji i zanotuj pytania, aby zadać je personelowi medycznemu.
Wydrukuj tę stronę CC-92480-MM-002
Pobierz przewodnik

WYBIERZ JĘZYK

Szczegóły badania

  • Phase 1/Phase 2

    Etap

  • Płeć

  • 18+

    Zakres wieku

  • 26

    Lokalizacje

  • Recruiting

Opcje leczenia

Grupy badania
PRZYPISANA INTERWENCJA
Experimental: CC-92480 in combination with bortezomib and dexamethasone
Drug: CC-92480, Bortezomib, Dexamethasone
Experimental: CC-92480 in combination with carfilzomib and dexamethasone
Drug: Elotuzumab, CC-92480, Dexamethasone
Experimental: CC-92480 in combination with daratumumab and dexamethasone
Drug: CC-92480, Dexamethasone, Carfilzomib
Experimental: Cohort D: CC-92480 with bortezomib and dexamethasone
Drug: Dexamethasone, CC-92480, Carfilzomib
Experimental: Cohort E: CC-92480 with daratumumab and dexamethasone
Drug: CC-92480, Dexamethasone, Elotuzumab
Experimental: Cohort F: CC-92480 with carfilzomib and dexamethasone
Drug: CC-92480, Dexamethasone, Isatuximab
Experimental: Cohort G: CC-92480 with bortezomib and dexamethasone
Drug: CC-92480, Dexamethasone, Daratumumab
Experimental: Cohort H: CC-92480 with elotuzumab and dexamathasone
Drug: CC-92480, Dexamethasone, Isatuximab
Experimental: Cohort I: CC-92480 with isatuximab and dexamathasone
Drug: CC-92480, Bortezomib, Dexamethasone
Experimental: Cohort J: CC-92480 with elotuzumab and dexamathasone
Drug: CC-92480, Bortezomib, Dexamethasone
Experimental: Cohort K: CC-92480 with isatuximab and dexamathasone
Drug: CC-92480, Dexamethasone, Daratumumab
Experimental: Subcohort B3: CC-92480 with daratumumab and dexamethasone
Drug: CC-92480, Daratumumab, Dexamethasone
Experimental: Subcohort E1: CC-92480 with daratumumab and dexamethasone
Drug: CC-92480, Daratumumab, Dexamethasone
Experimental: Subcohort E2: CC-92480 with daratumumab and dexamethasone
Drug: CC-92480, Dexamethasone, Daratumumab
Experimental: Subcohort E3: CC-92480 with daratumumab and dexamethasone
Drug: CC-92480, Daratumumab, Dexamethasone

Kluczowe kryteria kwalifikacyjne

Inclusion Criteria: 1. Subjects is ≥ 18 years of age and has an Eastern Cooperative Oncology Group (ECOG) performance status score of 0, 1 or 2. 2. Relapsed or refractory subjects must have measurable disease and have documented disease progression during or after their last anti-myeloma regimen. 3. Newly diagnosed subjects must have documented diagnosis with previously untreated symptomatic multiple myeloma. 4. Females of childbearing potential (FCBP) and male subjects must agree with the pregnancy prevention plan. Exclusion Criteria: 1. Subject has a significant medical condition, laboratory abnormality, or psychiatric illness that would prevent the subject from participating in the study. 2. Subject is unable or unwilling to undergo protocol required thromboembolism prophylaxis.